Welcome to our dedicated page for Brainsway Ltd. American Depositary Shares news (Ticker: $BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Brainsway Ltd. American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Brainsway Ltd. American Depositary Shares's position in the market.
Rhea-AI Summary
BrainsWay (BWAY) will report its Q1 2024 financial results and operational highlights on May 8, 2024. The company, a global leader in noninvasive neurostimulation treatments for mental health disorders, will host a conference call at 8:30 AM Eastern Time to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
-
News
Rhea-AI Summary
BrainsWay expands Deep TMS™ access in Israel with a 45% increase in reimbursement rates. The company installs the 11th system in Israel and plans for more installations by the end of 2024, aiming to offer life-altering therapy to mental health patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
-
Rhea-AI Summary
BrainsWay released clinical data from multiple trials showing improvements in both motor and non-motor symptoms for Parkinson's Disease. The review article highlighted the potential efficacy of Deep Transcranial Magnetic Stimulation (Deep TMS™) in treating PD, with positive outcomes observed in motor symptoms and daily living improvements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
Rhea-AI Summary
BrainsWay (BWAY) announces positive results in a post-marketing study for late-life depression treatment using Deep Transcranial Magnetic Stimulation (Deep TMS™). The study showed a 79.4% response rate and a 60.3% remission rate in patients aged 60-91, addressing concerns about efficacy in older adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
-
Rhea-AI Summary
BrainsWay announces that Katie's Way Plus has ordered an additional 18 Deep TMS systems to expand its mental health services for servicemembers, veterans, and their families. This partnership aims to provide specialized care using advanced technology to address the rising prevalence of mental health conditions within the veteran community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
-
News
Rhea-AI Summary
BrainsWay Ltd. (BWAY) reported record revenues in Q4 2023 with a 50% year-over-year growth, achieving positive net income. The company provided a revenue guidance of $37-$40 million for full-year 2024, showcasing continued profitability and cash generation. BrainsWay's financial and operational highlights included increased revenues, improved gross margins, positive operating income, net income, and Adjusted EBITDA. The company also expanded its Deep TMS installed base, collaborated with mental health providers, and enhanced reimbursement trends. BrainsWay's CEO highlighted the strong performance in 2023, anticipating revenue growth in 2024 and positioning the company as a leader in the TMS industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
BrainsWay Ltd. (BWAY) announces the reporting of its Q4 and full year 2023 financial results and operational highlights on March 6, 2024. The Company will host a conference call to discuss the results and provide business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
-
Rhea-AI Summary
BrainsWay Ltd. (BWAY) to clinically evaluate innovative stimulation technology in two new feasibility trials. The patented 'Rotational Field' TMS aims to stimulate a greater number of neurons in the brain, potentially impacting patients with stroke and obsessive-compulsive disorder (OCD). The technology is not yet FDA-cleared, but the company aims to assess its potential clinical impact in the new studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
-
Rhea-AI Summary
BrainsWay Ltd. (NASDAQ & TASE: BWAY) announced increased collaboration with a growing mental health treatment provider in the Western US. The provider will receive seven Deep Transcranial Magnetic Stimulation (Deep TMS™) systems, with plans for further expansion. BrainsWay aims to improve access to non-drug mental health treatments for depression, OCD, and smoking addiction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.48%
Tags
Rhea-AI Summary
BrainsWay Ltd. (NASDAQ & TASE: BWAY) announced expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in South Korea. Recent sales are expected to bring BrainsWay’s installed base in the country to over 20 Deep TMS systems. The company's CEO, Hadar Levy, expressed satisfaction with the increasing traction of their state-of-the-art technology in South Korea, emphasizing its positive impact on mental health patients. The Deep TMS system, delivered through a patented coil design, is capable of stimulating important neural networks in the brain. BrainsWay’s unique therapeutic solution is currently cleared in South Korea to treat major depressive disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
Brainsway Ltd. American Depositary Shares
Nasdaq:BWAY
BWAY Rankings
BWAY Stock Data
96.83M
24.69M
5.01%
24.07%
0.45%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
Jerusalem
About BWAY
brainsway is a leading global neurmodulation company with headquarters in jerusalem and the us. our patented breakthrough technology has already treated over 10,000 patients, and has helped usher in a new era in brain disorder treatment. a non-invasive, yet highly effective solution for brain disorders, brainsway has helped thousands of patients across the world, from the unites states to europe to south america, and has the potential to make a difference in the well-being and health of millions of patients worldwide. brainsway's technology offers a much needed alternative for millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. brainsway's treatment has fda approval for treating patients with major depressive disorder*. the technology is safe, with no systemic or long-term side effects, in addition to being highly convenient, requiring only brief daily sessions over a few weeks. in addition to being used to treat depression daily